Study summary
Sparsentan lowered protein in the urine more than irbesartan, though kidney function decline was similar
42.0%partial remission of proteinuria at 36 weeks, vs 26.0%
What was tested
Sparsentan, a daily pill that blocks both endothelin and angiotensin receptors, against irbesartan (a standard blood pressure drug that protects the kidneys), for 108 weeks in people aged 8 to 75 with FSGS.
What they found
- Partial remission of proteinuria at 36 weeks: 42.0% with sparsentan vs 26.0% with irbesartan, sustained through 108 weeks.
- The rate of kidney function (eGFR) decline did not differ significantly.
- Safety was similar.
What it means
Basis for the first FDA approval for FSGS in April 2026.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.